In detail, 3 out of 6 patients with Burkitt’s lymphoma, who underwent CD19- and CD22-redirected CAR-T therapy, achieved an objective response (two partial responses; one CR) (52). This evidence concerns the gene CD19 and Burkitt lymphoma.